Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,699 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview.
Crucitta S, Cucchiara F, Sciandra F, Cerbioni A, Diodati L, Rafaniello C, Capuano A, Fontana A, Fogli S, Danesi R, Re MD. Crucitta S, et al. Among authors: fontana a. Anticancer Agents Med Chem. 2022;22(4):760-774. doi: 10.2174/1871520621666210804100547. Anticancer Agents Med Chem. 2022. PMID: 34348634 Review.
Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G. Fontana A, et al. Among authors: fontana e. Clin Cancer Res. 2009 Aug 1;15(15):4954-62. doi: 10.1158/1078-0432.CCR-08-3317. Epub 2009 Jul 21. Clin Cancer Res. 2009. PMID: 19622584 Clinical Trial.
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G. Allegrini G, et al. Among authors: fontana a. Angiogenesis. 2012 Jun;15(2):275-86. doi: 10.1007/s10456-012-9260-6. Epub 2012 Mar 2. Angiogenesis. 2012. PMID: 22382585 Free PMC article.
Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G. Derosa L, et al. Among authors: fontana a. Cancer. 2014 Dec 15;120(24):3923-31. doi: 10.1002/cncr.28953. Epub 2014 Aug 8. Cancer. 2014. PMID: 25111199 Free article. Clinical Trial.
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
Allegrini G, Coltelli L, Orlandi P, Fontana A, Camerini A, Ferro A, Cazzaniga M, Casadei V, Lucchesi S, Bona E, Di Lieto M, Pazzagli I, Villa F, Amoroso D, Scalese M, Arrighi G, Molinaro S, Fioravanti A, Finale C, Triolo R, Di Desidero T, Donati S, Marcucci L, Goletti O, Del Re M, Salvadori B, Ferrarini I, Danesi R, Falcone A, Bocci G. Allegrini G, et al. Among authors: fontana a. Pharmacogenomics. 2014 Dec;15(16):1985-99. doi: 10.2217/pgs.14.140. Pharmacogenomics. 2014. PMID: 25521357 Clinical Trial.
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.
Solini A, Simeon V, Derosa L, Orlandi P, Rossi C, Fontana A, Galli L, Di Desidero T, Fioravanti A, Lucchesi S, Coltelli L, Ginocchi L, Allegrini G, Danesi R, Falcone A, Bocci G. Solini A, et al. Among authors: fontana a. Oncotarget. 2015 Oct 6;6(30):28743-54. doi: 10.18632/oncotarget.4926. Oncotarget. 2015. PMID: 26337470 Free PMC article.
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.
Di Desidero T, Derosa L, Galli L, Orlandi P, Fontana A, Fioravanti A, Marconcini R, Giorgi M, Campi B, Saba A, Lucchesi S, Felipetto R, Danesi R, Francia G, Allegrini G, Falcone A, Bocci G. Di Desidero T, et al. Among authors: fontana a. Invest New Drugs. 2016 Dec;34(6):760-770. doi: 10.1007/s10637-016-0385-0. Epub 2016 Aug 24. Invest New Drugs. 2016. PMID: 27557783 Clinical Trial.
ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer.
La Ferla M, Lessi F, Aretini P, Pellegrini D, Franceschi S, Tantillo E, Menicagli M, Marchetti I, Scopelliti C, Civita P, De Angelis C, Diodati L, Bertolini I, Roncella M, McDonnell LA, Hochman J, Del Re M, Scatena C, Naccarato AG, Fontana A, Mazzanti CM. La Ferla M, et al. Among authors: fontana a. Front Oncol. 2019 Jun 26;9:547. doi: 10.3389/fonc.2019.00547. eCollection 2019. Front Oncol. 2019. PMID: 31297336 Free PMC article.
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Del Re M, Bertolini I, Crucitta S, Fontanelli L, Rofi E, De Angelis C, Diodati L, Cavallero D, Gianfilippo G, Salvadori B, Fogli S, Falcone A, Scatena C, Naccarato AG, Roncella M, Ghilli M, Morganti R, Fontana A, Danesi R. Del Re M, et al. Among authors: fontana a. Breast Cancer Res Treat. 2019 Nov;178(1):57-62. doi: 10.1007/s10549-019-05365-y. Epub 2019 Jul 26. Breast Cancer Res Treat. 2019. PMID: 31346846
1,699 results